Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. [electronic resource]

By:

Bester, A C

Contributor(s):

Schwartz, M
Schmidt, M
Garrigue, A
Hacein-Bey-Abina, S
Cavazzana-Calvo, M
Ben-Porat, N
Von Kalle, C
Fischer, A
Kerem, B

Producer: 20060915Description: 1057-9 p. digitalISSN:

0969-7128

Subject(s):

Cells, Cultured
Chromosome Fragile Sites
Chromosome Fragility
Genetic Therapy -- adverse effects
Genetic Vectors -- adverse effects
HeLa Cells -- virology
Humans
Leukemia -- immunology
Leukemia Virus, Murine -- genetics
Mutagenesis, Insertional
Risk Assessment
Severe Combined Immunodeficiency -- genetics
T-Lymphocytes -- virology
Virus Integration -- genetics

Online resources:

Available from publisher's website

In: Gene therapy vol. 13

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.

APA

Bester A. C., Schwartz M., Schmidt M., Garrigue A., Hacein-Bey-Abina S., Cavazzana-Calvo M., Ben-Porat N., Von Kalle C., Fischer A. & Kerem B. (20060915). Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. : Gene therapy.

Chicago

Bester A C, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A and Kerem B. 20060915. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. : Gene therapy.

Harvard

Bester A. C., Schwartz M., Schmidt M., Garrigue A., Hacein-Bey-Abina S., Cavazzana-Calvo M., Ben-Porat N., Von Kalle C., Fischer A. and Kerem B. (20060915). Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. : Gene therapy.

MLA

Bester A C, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, Von Kalle C, Fischer A and Kerem B. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. : Gene therapy. 20060915.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC